Home > Medical Research Archives > Issue 149 > Castration-Synchronized Upfront Docetaxel for metastatic Hormone Sensitive Prostate Cancer considering Epithelial to Mesenchymal Transition
![](https://esmed.org/wp-content/uploads/2022/12/MRA-cover-150x150.png)
Published in the Medical Research Archives
Oct 2022 Issue
Castration-Synchronized Upfront Docetaxel for metastatic Hormone Sensitive Prostate Cancer considering Epithelial to Mesenchymal Transition
Published on Oct 31, 2022
DOI
Abstract
Upfront docetaxel therapy for metastatic hormone sensitive prostate cancer (mHSPC) has been reported to be improved outcome, although the best timing to start decetaxel and/or the duration of chemotherapy have not been cleared. We consider epithelial to mesenchymal transition (EMT) at the beginning of the hormonal therapy would be the mechanism to obtain apoptosis tolerance of prostatic cells. For localized prostate cancer, we used LH-RH antagonist (degarelix) twice and performed high-intensity focused ultrasound therapy (HIFU) after two weeks of the first degarelix, the timing of inducing EMT. This regimen apparently improved HIFU results. So for mHSPC, we started two to three courses of upfront docetaxel synchronously the beginning of the androgen deprivation therapy (ADT). Of 38 mHSPC patients underwent upfront docetaxel with our protocol, 18 patients maintained low prostate specific antigen value less than 0.1 ng/ml for more than two years without adding new androgen axis targeted therapy agents (ARAT). Although recent study suggests all mHSPC patients should receive systemic triple therapy including ADT, docetaxel and ARAT, our study indicated that upfront docetaxel use considering EMT may select the patients requiring triple therapy, and reduce a burden both for the patients and medical economy.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member